Keeping abreast with the latest developments in adult vaccination is crucial for healthcare professionals. This article aims to provide an overview of recent advancements in the field, focusing on the most significant updates that have implications for adult immunization practices.
Undoubtedly, the most significant development in adult vaccination over the past year has been the rapid development and authorization of vaccines against SARS-CoV-2. Notably, mRNA vaccines such as the Pfizer-BioNTech and Moderna vaccines have demonstrated high efficacy and safety profiles. Furthermore, Johnson & Johnson's single-dose vaccine and AstraZeneca's viral vector vaccine have also been authorized for emergency use.
The recombinant zoster vaccine (RZV), Shingrix, has been recommended over the live zoster vaccine (ZVL), Zostavax, due to its superior efficacy and longevity of protection. The Centers for Disease Control and Prevention (CDC) now recommends two doses of RZV for adults aged 50 and older, even if they have previously received ZVL.
The quadrivalent influenza vaccine is now the standard for annual influenza vaccination in adults. It protects against two influenza A viruses and two influenza B viruses. High-dose and adjuvanted influenza vaccines are available for adults aged 65 and older, providing better protection for this age group.
The CDC now recommends a sequence of pneumococcal conjugate vaccine (PCV13) followed by pneumococcal polysaccharide vaccine (PPSV23) for all adults aged 65 and older, and for adults younger than 65 with certain risk factors.
In conclusion, the field of adult vaccination is rapidly evolving, with significant updates in various areas. Healthcare professionals must stay updated to ensure the best possible patient outcomes. Continued research and development in this field promises to bring further improvements in the prevention of infectious diseases in adults.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation